Mercosur · Pharmaceuticals · Biologics · Biosimilars · EU Trade
Mercosur Pharma 2026: Three Scenarios for Brazil and Argentina
The trade context changed on 1 May 2026, when the EU-Mercosur Interim Trade Agreement began provisional application. Brazil remains the scale market, Argentina combines export capability with a widening medicine trade deficit, and biologics and biosimilars are becoming a more important test of whether Mercosur can develop deeper pharmaceutical capacity.
Mercosur pharma is becoming more integrated in trade while remaining fragmented in regulation, procurement and industrial capability.
Since 1 May 2026, the EU-Mercosur Interim Trade Agreement has provisionally applied and pharmaceutical tariffs of up to 14% have begun a ten-year phase-down toward zero for 90% of EU exports. That changes the commercial baseline, but it does not turn Brazil, Argentina, Paraguay and Uruguay into one pharmaceutical market.
Brazil provides scale and a large biologics demand base. Argentina has meaningful local manufacturing, biotechnology and export capacity, yet its medicine trade deficit widened to US$1.873 billion in 2025. The region's next phase therefore depends on whether tariff integration is followed by regulatory cooperation and deeper production capability.
The strongest signal is the mismatch between market growth and industrial autonomy. Brazil has the scale to anchor regional demand. Argentina can export more medicines and develop biosimilar capability while still importing far more pharmaceutical value than it exports. Paraguay and Uruguay remain smaller access markets.
The three scenarios in this analysis therefore track different layers of the market: trade integration, regulatory fragmentation and selective biologics and biosimilar industrialization.
For the sector-wide view beyond this scenario analysis, see Econosur's Pharma in South America industry hub, which compares the different roles of Brazil, Argentina, Paraguay and Uruguay and links the current company cases across the region.
What Changed in Mercosur Pharma in 2026?
The May version of this analysis treated EU-Mercosur implementation as a future trigger. That is no longer accurate. The Interim Trade Agreement (iTA) has applied provisionally since 1 May 2026, so the trade pillar has moved from expectation into implementation.
Pharmaceuticals are directly affected. The European Commission states that current Mercosur pharma tariffs of up to 14% have started a ten-year transition to zero for 90% of EU exports, with a first tariff cut of up to 1.3 percentage points on day one.
The legal architecture is still incomplete. The broader EU-Mercosur Partnership Agreement (EMPA) requires European Parliament consent and ratification by all EU member states and Mercosur parties. The European Parliament requested a Court of Justice opinion in January 2026 and is awaiting that opinion before voting on consent.
“The relevant question is no longer whether tariff liberalisation starts. It has started. The question is whether lower tariffs translate into actual market access, regulatory cooperation and deeper regional production.”
Brazil Is the Scale Anchor — and Biologics Are the Important New Signal
Brazil remains the market that determines whether a Mercosur pharmaceutical strategy has commercial scale. ANVISA's CMED annual report puts 2024 pharmaceutical market revenue at R$160.7 billion, up 12.8% nominally from 2023, with more than six billion packages sold.
The more important sector signal is inside that total. Biological medicines generated R$48.5 billion in 2024, up 25.9%, and represented around 30% of market revenue. This does not prove that biosimilars already dominate Brazilian biologics. It does show that biological therapies are commercially large enough for biosimilar competition, local partnerships and affordability pressure to matter.
For market entry, Brazil still means ANVISA regulation, CMED pricing rules, public and private procurement, distribution and a strong domestic industry. Econosur's Brazil market profile provides the broader economic and industrial context, while the Brazil insights section tracks current market shifts beyond pharmaceuticals.
R$48.5 billion of biological-medicine revenue creates a meaningful commercial base for originators, biosimilars, hospital channels and specialist distribution.
Lower import duties improve economics, but ANVISA approval, CMED pricing, procurement and local commercial execution remain decisive.
Argentina's Export Record Masks a Larger Import Dependency
Argentina is strategically different from Brazil. It has a long-established pharmaceutical industry, local research and manufacturing capability, biotechnology assets and a record of regional exports. But the external-trade data show a structural constraint.
CILFA's calculations based on INDEC data show medicine exports of US$1.169 billion in 2025, a record and 17.5% above 2024. Imports rose faster, to US$3.042 billion, widening the medicine trade deficit from about US$1.49 billion in 2024 to US$1.873 billion in 2025.
The first five months of 2026 preserved the same tension. Total Argentine medicine exports were still 4.4% higher year on year, but import activity remained elevated. Export growth therefore cannot be read as evidence that the upstream dependency problem has been solved.
Argentina's regulatory position is also moving. ANMAT's Disposición 1741/2025 establishes comparability requirements for biosimilar medicines. In July 2026, Disposición 4351/2026 created a new framework for post-registration changes to biological medicines and introduced a reliance route that can use assessments from reference regulators under defined conditions.
The wider business context is covered in Econosur's Argentina market profile and Argentina market insights.
Local medicine production is not the same as industrial autonomy. Argentina can export finished medicines while remaining dependent on imported products, active ingredients, advanced biological inputs, equipment and other upstream components.
The US$1.873 billion sectoral deficit is therefore not a contradiction to the export story. It is the evidence that completes it.
Companies to Watch in the Mercosur Pharma Market
The company landscape is broader than any one ranking. The names below are useful because they represent different parts of the market: domestic scale, regional expansion, generics, biologics, biosimilars and biotechnology manufacturing. Inclusion is illustrative, not an investment recommendation or market-share ranking.
| Company | Market | Why it matters to the scenarios |
|---|---|---|
| EMS | Brazil | Large domestic pharmaceutical group with strong exposure to generics and branded medicines; relevant to Brazil's scale and affordability dynamics. |
| Eurofarma | Brazil / regional | Brazilian multinational with a broad Latin American footprint; a useful example of regional pharmaceutical expansion beyond one national market. |
| Aché | Brazil | Established Brazilian pharmaceutical manufacturer; relevant to local production, product development and domestic competition. |
| Libbs | Brazil | Directly relevant to the biosimilar scenario through biologics activity and recent biosimilar licensing partnerships in Brazil. |
| Roemmers · Bagó · Gador | Argentina | Established Argentine pharmaceutical groups that illustrate the depth of the country's locally rooted industry and regional commercial base. |
| Elea | Argentina | Direct biosimilar relevance: the company develops and commercializes biotechnology products and publicly highlights locally produced monoclonal-antibody biosimilars. |
| Laboratorios Richmond | Argentina / regional | Regional pharmaceutical company whose portfolio includes generics and biosimilars, making it relevant to the selective industrial-upgrading scenario. |
| mAbxience | Argentina-linked / global | Biosimilar and biologics specialist with manufacturing capability in Argentina; relevant to the region's ability to participate in higher-complexity biopharmaceutical production. |
| Laboratorios LASCA | Paraguay | Shows how a smaller Mercosur market can build local pharmaceutical manufacturing, biologics capability and export-grade regulatory qualification. |
| Megalabs | Uruguay / regional | Shows how Uruguay can function as a regional pharmaceutical platform for manufacturing, R&D, corporate functions and distribution into larger Latin American markets. |
The strongest company signal is not that Mercosur has a single regional champion. It is that Brazil and Argentina already contain different pieces of a regional pharmaceutical system: scale manufacturers, generics specialists, biologics companies, biosimilar developers and internationally connected production platforms.
Paraguay and Uruguay Add Two Different Industrial Models
Paraguay and Uruguay remain much smaller pharmaceutical demand markets than Brazil and Argentina, but the new company evidence shows that neither should be treated as a simple import-and-distribution market.
In Paraguay, Laboratorios LASCA demonstrates a path of domestic manufacturing → biologics capability → external GMP qualification → exports. Its 2023 INVIMA certification for the biologics plant is a concrete example of industrial upgrading in a smaller Mercosur economy.
Uruguay plays a different role. Megalabs uses its Uruguay base for manufacturing, regional R&D, quality control, corporate functions and distribution. That makes Uruguay less a small end market than a regional operating platform linked to larger destinations such as Argentina and Brazil.
The distinction matters to the three scenarios. Paraguay strengthens the case for selective industrial deepening outside the two largest markets. Uruguay strengthens the case for operational regional integration even when regulation remains nationally fragmented.
For the sector-wide comparison, see the Pharma in South America industry hub, together with Econosur's Paraguay market profile, analysis of Paraguay's role in Mercosur and Uruguay market profile.
EU-Mercosur Is Now a Trade Reality — but Not a Finished Institutional Settlement
The distinction between the two agreements matters. The Interim Trade Agreement contains the trade and investment liberalisation pillar and is already being applied provisionally. The broader EU-Mercosur Partnership Agreement adds political dialogue and cooperation and still requires the remaining European and national ratification steps.
For pharmaceuticals, the iTA reduces one measurable barrier: tariffs. But tariff cuts do not harmonize ANVISA and ANMAT, eliminate national pricing systems, standardize public procurement or create automatic authorization across Mercosur.
The institutional uncertainty is also real. On 21 January 2026, the European Parliament voted 334 to 324 to ask the Court of Justice for an opinion on the compatibility of the EMPA and iTA with the EU treaties. Parliament continues examining the texts but states that it will vote on consent only after receiving the Court's opinion.
The Hidden Dependency Is Upstream: APIs, Biologics Inputs and Specialized Supply
Mercosur can have strong final-formulation companies and still depend heavily on external upstream supply. The Inter-American Development Bank has highlighted Latin America's limited participation in higher-value parts of the pharmaceutical global value chain and the importance of imported active pharmaceutical ingredients and other inputs.
Argentina's 2025 trade balance illustrates the issue. Record medicine exports coexisted with much larger imports. Brazil's scale provides more room for local production and supplier development, but scale alone does not guarantee autonomy in APIs, advanced biological inputs, specialized manufacturing technology or equipment.
This is why the pharmaceutical story should not be framed as reshoring everything. A more realistic industrial path is selective: stronger formulation, generics, biosimilars, fill-finish, quality systems, packaging, cold chain and specific biotechnology capabilities while upstream dependencies remain.
Scenario 1: Integration Accelerator
Trade integration begins to produce commercial integration.
EU tariff preferences are used in practice, regional companies expand distribution and production footprints, and regulators improve reliance or cooperation mechanisms without fully harmonizing their systems.
This scenario is more plausible than it was in May because one trigger has already occurred: provisional application of the iTA. The next test is utilization. Companies need to show that lower tariffs translate into actual shipments, investment, product registration and more predictable market entry.
Companies with regional footprints, including Eurofarma and Argentine groups with cross-border commercial operations, would be better positioned than firms approaching Mercosur as four unrelated export destinations. European originator and specialty-pharma companies could also benefit from lower tariff friction, but national regulatory and pricing systems would remain decisive.
Signals that would strengthen Scenario 1
- Measurable use of iTA tariff preferences in pharmaceutical trade.
- Faster or more predictable reliance procedures between reference regulators and national authorities.
- More regional licensing, distribution and manufacturing partnerships.
- Cross-border investment in packaging, quality systems, cold chain and specialist manufacturing.
Scenario 2: Fragmentation Trap
Tariffs fall, but the commercial market remains national.
ANVISA, ANMAT and smaller-market regulators continue to require separate strategies; pricing, procurement and reimbursement remain country-specific; and the wider EMPA ratification process stays politically or legally uncertain.
This scenario does not require the iTA to fail. Trade liberalisation can coexist with fragmented regulation. A European pharmaceutical company may face lower import duties while still needing separate registrations, local representation, pricing work, tenders and distribution structures in each market.
Paraguay and Uruguay are especially useful indicators. If integration does not improve practical access and supply reliability for smaller markets, Mercosur will still function mainly as a tariff framework rather than a pharmaceutical operating platform.
“A tariff agreement can integrate trade faster than it integrates regulators, procurement systems or industrial capabilities.”
Signals that would strengthen Scenario 2
- Low utilization of pharmaceutical tariff preferences.
- Persistent duplication of regulatory dossiers and market-entry procedures.
- Limited cross-border industrial investment despite stronger demand.
- Continued import dependence without deeper regional supply-chain capability.
- Extended uncertainty around EMPA consent and ratification.
Scenario 3: Biosimilar Corridor
Brazilian biologics demand and Argentine biotechnology capability create a more specialized regional corridor.
The model does not require a single Mercosur regulator. It requires commercially relevant biologics demand, biosimilar competition, capable manufacturers, workable reliance mechanisms and enough market access to scale across borders.
The demand-side case is stronger than it was in the original article. Brazil's biological-medicine segment reached R$48.5 billion in 2024 and grew 25.9%. That figure measures biologics overall, not biosimilars alone, so it should not be treated as proof of biosimilar penetration. It does show that the therapeutic segment is large enough for affordability and competition to become strategically important.
The supply-side case is also concrete. Argentina has a biosimilar comparability framework under Disposición 1741/2025, and companies such as Elea, Laboratorios Richmond and mAbxience already demonstrate local or Argentina-linked biosimilar and biologics capability. In Brazil, Libbs provides an example of a domestic company using licensing partnerships to expand biosimilar access.
That still falls short of a proven regional corridor. Manufacturing scale, regulatory acceptance, reference-product rules, pricing, public procurement, IP, financing and distribution all determine whether separate national capabilities become a repeatable cross-border model.
Signals that would strengthen Scenario 3
- More biosimilar approvals and launches in Brazil and Argentina.
- Regional licensing or manufacturing agreements tied to Mercosur distribution.
- Greater use of regulatory reliance without loss of national oversight.
- Investment in biologics manufacturing, fill-finish, quality control and cold-chain capacity.
- Evidence that public and private payers are using biosimilars to widen access or reduce treatment costs.
The Three Scenarios Can Happen at the Same Time
The most likely outcome is layered rather than binary. Mercosur can integrate tariffs while remaining fragmented in product authorization. Brazil can deepen biologics demand while Argentina develops selected biosimilar capabilities. Paraguay can deepen selected manufacturing capabilities while Uruguay captures value through regional platform functions, even without matching the scale of Brazil or Argentina.
For companies, the practical question is therefore not whether Mercosur is “one market.” The useful question is which layer is integrating, which layer remains national and which pharmaceutical capabilities are becoming regional.
Strategic Implications for Pharmaceutical and B2B Companies
| Company type | Primary opportunity | Main constraint |
|---|---|---|
| EU finished-medicine exporters | Gradually lower tariff burden under the iTA. | National authorization, pricing, procurement and distribution. |
| Generics & biosimilar producers | Affordability pressure and a large Brazilian biologics base. | Scale, regulatory comparability, pricing and payer adoption. |
| Local pharma groups | Regional licensing, exports and partnership models. | Capital intensity and upstream import dependence. |
| Equipment & service suppliers | Cleanrooms, lab equipment, QC, packaging, serialization, cold chain and validation. | Project timing, qualification and local procurement structures. |
| Market-entry teams | More predictable tariff framework and growing demand. | Mercosur still requires country-specific regulatory and commercial execution. |
What to Watch Next
The tariff schedule is now active. The next meaningful evidence is whether pharmaceutical trade actually shifts because companies use the preferences.
The iTA continues provisionally, but the broader EMPA still depends on Parliament consent and national ratification. The CJEU opinion is a material institutional watchpoint.
Track whether strong biologics revenue growth is followed by more biosimilar launches, licensing agreements and payer adoption.
Export growth is positive, but the larger question is whether imports and upstream dependence continue to expand faster than local external sales.
Disposición 1741/2025 and the 2026 post-registration framework matter only if they translate into predictable approvals, lifecycle management and workable reliance.
The Econosur Reading
Mercosur pharma is no longer best described as a future trade-agreement story. The trade pillar is already being applied. That makes the analytical test more demanding: tariff cuts now have to be separated from regulatory integration and from industrial capability.
Brazil supplies the scale and the largest biologics demand signal. Argentina supplies a second industrial and biotechnology pole, but its widening medicine trade deficit shows that stronger exports do not remove upstream dependence. Paraguay and Uruguay show two additional paths: selective industrial upgrading in Paraguay and regional platform functions in Uruguay.
The Integration Accelerator now has a live tariff mechanism. The Fragmentation Trap remains plausible because national regulatory and procurement systems persist and the full EMPA is not yet settled. The Biosimilar Corridor has stronger empirical support through Brazil's biologics market and identifiable companies with biosimilar capability, but it remains a scenario rather than an established regional production system. LASCA and Megalabs broaden the picture by showing that smaller Mercosur economies can contribute through export-qualified manufacturing and regional platform functions even when they do not anchor biologics demand at Brazilian scale.
This update prioritizes EU institutions, national regulators and industry data derived from official trade statistics. Company sources are used only for their own stated capabilities or partnerships.
- European Commission — provisional application of the EU-Mercosur agreement and pharmaceutical tariff schedule
- Council of the EU — distinction between the Interim Trade Agreement and Partnership Agreement
- European Parliament — January 2026 request for a Court of Justice opinion
- ANVISA / CMED — Anuário Estatístico do Mercado Farmacêutico 2024
- CILFA — Argentina medicine trade, full-year 2025, based on INDEC
- CILFA — Argentina medicine trade, first five months of 2026
- ANMAT — Disposición 1741/2025 on biosimilar comparability
- ANMAT — Disposición 4351/2026 and post-registration changes for biological medicines
- Inter-American Development Bank — pharmaceutical global value chain in Latin America and the Caribbean
- EMS — company profile and pharmaceutical portfolio
- Eurofarma — company and regional footprint
- Aché — company, manufacturing and biotechnology profile
- Roemmers — company and manufacturing profile
- Laboratorios Bagó — company profile and international presence
- Gador — company, production and international market profile
- Laboratorio Elea — biotechnology and biosimilar research
- Laboratorios Richmond — generics and biosimilars portfolio
- mAbxience — biologics and biosimilar development and manufacturing
- Econosur — Laboratorios LASCA company insight
- Econosur — Megalabs company insight
- Polpharma Biologics / Libbs — 2025 Brazilian biosimilar licensing agreement
South America Pharmaceutical Market Analysis
Econosur prepares custom market analysis for pharmaceutical manufacturers, suppliers and B2B service companies evaluating Brazil, Argentina, Paraguay, Uruguay and the wider South American market.
Analysis can cover market structure, companies, regulation, distribution, import dependence, supplier landscapes, industrial capacity and market-entry conditions.
Explore custom market analysisFrequently Asked Questions
Is Mercosur one pharmaceutical market?
No. Brazil, Argentina, Paraguay and Uruguay remain separate pharmaceutical markets with different regulators, industrial depth, procurement systems and import dependence. Mercosur creates a regional trade framework, but pharmaceutical market access remains country-specific.
What changed for pharmaceuticals under the EU-Mercosur agreement in 2026?
The Interim Trade Agreement has applied provisionally since 1 May 2026. Pharmaceutical tariffs of up to 14% began a ten-year transition toward zero for 90% of EU exports, with an initial tariff cut of up to 1.3 percentage points.
Is the full EU-Mercosur Partnership Agreement in force?
No. The Interim Trade Agreement is provisionally applied, while the broader Partnership Agreement still requires European Parliament consent and ratification by all EU member states and Mercosur parties. Parliament is awaiting a Court of Justice opinion on the legal compatibility of the agreements.
Why is Brazil central to Mercosur pharma?
Brazil is the region's scale anchor. ANVISA and CMED reported pharmaceutical market revenue of R$160.7 billion in 2024, while biological medicines accounted for R$48.5 billion, about 30% of market revenue.
What is the key contradiction in Argentina's pharmaceutical sector?
Argentina reached record medicine exports of US$1.169 billion in 2025, but imports rose to US$3.042 billion and the sectoral trade deficit widened to US$1.873 billion. Export capability therefore does not equal upstream industrial autonomy.
Can Argentina become a biosimilar production hub?
Argentina has relevant biotechnology and biosimilar capabilities and ANMAT strengthened the regulatory framework through Disposición 1741/2025. Companies such as Elea, Laboratorios Richmond and mAbxience show that local capability exists, but a regional hub still depends on scale, regulatory execution, financing and export access.
Does Brazil's biologics growth prove a biosimilar corridor already exists?
No. Brazil's R$48.5 billion biologics segment demonstrates the commercial importance of biological therapies, not biosimilar penetration by itself. The corridor scenario requires a combination of biologics demand, biosimilar competition, manufacturing capability, regulation and cross-border market access.
What are the three Mercosur pharma scenarios?
The three scenarios are Integration Accelerator, Fragmentation Trap and Biosimilar Corridor. They can overlap: tariff integration may advance while regulation remains fragmented and selected biologics or biosimilar capabilities deepen across Brazil and Argentina.
